Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors - PubMed (original) (raw)

Clinical Trial

Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors

Bruce J Giantonio et al. Clin Cancer Res. 2004.

Abstract

Purpose: A Phase I trial was performed to determine the dose-limiting toxicity and maximum tolerated dose, and to describe the pharmacokinetics of the alkyl-lysophospholipid, ilmofosine, when administered as a weekly 2-h infusion in patients with solid tumors.

Experimental design: Thirty-nine patients were entered into a trial of ilmofosine administered weekly for 4 weeks followed by a 2-week rest period. Dose escalation occurred in 10 levels from 12 to 650 mg/m(2).

Results: Thirty-six patients were evaluable for toxicity. The median number of cycles per patient was 1 (range, 1-4). Dose-limiting gastrointestinal toxicity occurred at 650 mg/m(2) with grade 3 nausea in two patients and grade 3 vomiting and diarrhea in one patient. Grade 2 diarrhea was observed in four of six patients treated at 550 mg/m(2). In addition, two patients treated at 550 mg/m(2) and two patients treated at 650 mg/m(2) experienced a decline in performance status of two or more levels that was determined to be due to treatment. There were no tumor responses. Stabilization of disease for at least 8 weeks occurred in six patients. Plasma concentrations of ilmofosine and its sulfoxide metabolite were evaluated by high-pressure liquid chromatography. The elimination of both compounds was biexponential with terminal half-lives of approximately 40 h for ilmofosine and 48 h for the sulfoxide. The area under the concentration-time curve was dose-proportional for each compound, and there was no evidence of saturable kinetics.

Conclusions: The dose-limiting toxicity of ilmofosine is gastrointestinal and the recommended dose for Phase II trials is 450 mg/m(2) as a 2-h weekly infusion. The relatively long half-life of ilmofosine and its active metabolite support the use of this intermittent schedule.

PubMed Disclaimer

Cited by

Synthesis of ether lipids: natural compounds and analogues.
Gomes MAGB, Bauduin A, Le Roux C, Fouinneteau R, Berthe W, Berchel M, Couthon H, Jaffrès PA. Gomes MAGB, et al. Beilstein J Org Chem. 2023 Sep 8;19:1299-1369. doi: 10.3762/bjoc.19.96. eCollection 2023. Beilstein J Org Chem. 2023. PMID: 37701305 Free PMC article. Review.
AKT Isoforms as a Target in Cancer and Immunotherapy.
Smit DJ, Jücker M. Smit DJ, et al. Curr Top Microbiol Immunol. 2022;436:409-436. doi: 10.1007/978-3-031-06566-8_18. Curr Top Microbiol Immunol. 2022. PMID: 36243855
Targeting Protein Kinase C for Cancer Therapy.
He S, Li Q, Huang Q, Cheng J. He S, et al. Cancers (Basel). 2022 Feb 22;14(5):1104. doi: 10.3390/cancers14051104. Cancers (Basel). 2022. PMID: 35267413 Free PMC article. Review.
Akt isoforms differentially provide for chemoresistance in prostate cancer.
Ma B, Shao H, Jiang X, Wang Z, Wu CC, Whaley D, Wells A. Ma B, et al. Cancer Biol Med. 2021 Oct 1;19(5):635-50. doi: 10.20892/j.issn.2095-3941.2020.0747. Online ahead of print. Cancer Biol Med. 2021. PMID: 34591413 Free PMC article.
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).
Nitulescu GM, Margina D, Juzenas P, Peng Q, Olaru OT, Saloustros E, Fenga C, Spandidos DΑ, Libra M, Tsatsakis AM. Nitulescu GM, et al. Int J Oncol. 2016 Mar;48(3):869-85. doi: 10.3892/ijo.2015.3306. Epub 2015 Dec 24. Int J Oncol. 2016. PMID: 26698230 Free PMC article. Review.

Phase I and pharmacokinetic study of the cytotoxic ether lipid ilmofosine administered by weekly two-hour infusion in patients with advanced solid tumors - PubMed (original) (raw)